Immune-Onc Therapeutics, Inc. Announces Changes to Its Board of Directors
Immune-Onc Therapeutics, Inc. announced the appointments of Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D., to the company’s board of directors.
Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics. He was chief scientific officer, and senior vice president of research at OncoMed Pharmaceuticals. Prior to OncoMed, Austin worked at Genentech, where his research led to the discovery of several growth factors and cytokines.
Barbara J. Klencke, M.D. is a world-class drug developer and research & development expert, having made significant contributions to the oncology community with the development and approval of several first-in-class therapies. Since 2015, she has served as the chief medical officer of Sierra Oncology Inc.
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors.